JPS6256782B2 - - Google Patents
Info
- Publication number
- JPS6256782B2 JPS6256782B2 JP57212379A JP21237982A JPS6256782B2 JP S6256782 B2 JPS6256782 B2 JP S6256782B2 JP 57212379 A JP57212379 A JP 57212379A JP 21237982 A JP21237982 A JP 21237982A JP S6256782 B2 JPS6256782 B2 JP S6256782B2
- Authority
- JP
- Japan
- Prior art keywords
- gel
- adsorbent
- sulfate
- molecular weight
- ldl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000003463 adsorbent Substances 0.000 claims description 24
- 230000007717 exclusion Effects 0.000 claims description 24
- 102000004895 Lipoproteins Human genes 0.000 claims description 14
- 108090001030 Lipoproteins Proteins 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 12
- 229920000642 polymer Polymers 0.000 claims description 11
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 8
- 229920000669 heparin Polymers 0.000 claims description 8
- 229960002897 heparin Drugs 0.000 claims description 8
- 229920002567 Chondroitin Polymers 0.000 claims description 5
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 claims description 5
- 102000034238 globular proteins Human genes 0.000 claims description 5
- 108091005896 globular proteins Proteins 0.000 claims description 5
- 229920001282 polysaccharide Polymers 0.000 claims description 5
- 239000005017 polysaccharide Substances 0.000 claims description 5
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 claims description 4
- 229960000633 dextran sulfate Drugs 0.000 claims description 4
- 229920000447 polyanionic polymer Polymers 0.000 claims description 3
- 229920001059 synthetic polymer Polymers 0.000 claims description 3
- 230000003100 immobilizing effect Effects 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims 2
- 239000000499 gel Substances 0.000 description 40
- 102000007330 LDL Lipoproteins Human genes 0.000 description 24
- 108010007622 LDL Lipoproteins Proteins 0.000 description 24
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 17
- 238000000034 method Methods 0.000 description 15
- 239000011148 porous material Substances 0.000 description 15
- 239000002245 particle Substances 0.000 description 13
- 239000008280 blood Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 238000001179 sorption measurement Methods 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000003446 ligand Substances 0.000 description 8
- 125000003277 amino group Chemical group 0.000 description 7
- 239000000203 mixture Substances 0.000 description 6
- -1 succinylimide groups Chemical group 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical class [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 229910021645 metal ion Inorganic materials 0.000 description 4
- 239000012266 salt solution Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 229960002086 dextran Drugs 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 150000004804 polysaccharides Chemical class 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 125000003172 aldehyde group Chemical group 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 238000002616 plasmapheresis Methods 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 description 1
- PYSRRFNXTXNWCD-UHFFFAOYSA-N 3-(2-phenylethenyl)furan-2,5-dione Chemical compound O=C1OC(=O)C(C=CC=2C=CC=CC=2)=C1 PYSRRFNXTXNWCD-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 229920000288 Keratan sulfate Polymers 0.000 description 1
- 229920001543 Laminarin Polymers 0.000 description 1
- 239000005717 Laminarin Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000872931 Myoporum sandwicense Species 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229920000147 Styrene maleic anhydride Polymers 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000004018 acid anhydride group Chemical group 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- RUVINXPYWBROJD-UHFFFAOYSA-N anethole Polymers COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Polymers COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Landscapes
- External Artificial Organs (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Description
æ¬çºæã¯è¡æ¶²äžã®æ害æåã®é€å»çšã®åžçäœã«
é¢ãããããã«è©³ããã¯ãè¡æ¶²ãããã¯è¡æŒ¿ãè¡
æž äžãããªãèçœãç¹ã«äœå¯åºŠãªãèçœ
ïŒLDLïŒãéžæçã«åžçé€å»ããããã®åžçäœã«
é¢ããã è¡æ¶²äžã«ååšãããªãèçœã®ãã¡LDLã¯ã³ã¬
ã¹ãããŒã«ãå€ãå«ã¿ãåè硬åã®åå ãšãªãã
ãšãç¥ãããŠããããšããã家ææ§é«èè¡ççã®
é«ã³ã¬ã¹ãããŒã«çã§ã¯æ£åžžå€ã®æ°åã®LDLå€
ã瀺ããå åèã®ç¡¬åçãã²ããããããã®æ²»ç
ã®ãããè¡äžLDLã®äœäžãç®çãšããŠé£äºç
æ³ããããã³ãŒã«ãã³ã¬ã¹ãã©ãã³çã®è¬ç©çæ³
ãè¡ãªãããŠãããå¹æã«é床ããããå¯äœçšã
æžå¿µãããŠãããç¹ã«å®¶ææ§é«èè¡çã«å¯ŸããŠã¯
æ£è ã®è¡æŒ¿ãåé¢ããåŸãæ£åžžè¡æŒ¿ãããã¯ã¢ã«
ããã³çãæåãšããè£æ¶²ãšäº€æããããããã
è¡æŒ¿äº€æçæ³ãçŸåšã®ãšããã»ãŒå¯äžã®å¹æçãª
æ²»çæ³ã§ãããããããªããåšç¥ã®ããšãè¡æŒ¿äº€
æçæ³ã¯ãïŒïŒé«äŸ¡ãªæ°é®®è¡æŒ¿ãããã¯è¡æŒ¿è£œå€
ãçšããå¿ èŠããããïŒïŒèçããŒã«ã¹çã®ææ
ã®ãããããããïŒïŒæ害æåã®ã¿ã§ãªãæçšæ
åãåæã«é€å»ããŠããŸãçã®æ¬ ç¹ãæãããã
ããã®æ¬ ç¹ã解æ¶ããç®çã§èã«ããæ害æåã®
é€å»ãè©Šã¿ãããŠããããéžææ§ã®ç¹ã§æºè¶³ã§ã
ããã®ã¯ããŸã åŸãããŠããªãã ãŸãåãç®çã§æåãæäœçãåºå®ããããã
ãå ç«åžçäœãçšããè©Šã¿ããªãããŠããããã
ã¯éžææ§ã®ç¹ã§ã¯ã»ãŒæºè¶³ã§ãããã®ã®ãçšãã
æåãæäœã®å ¥æãå°é£ãã€é«äŸ¡ã§ãããšããèŽ
åœçãªæ¬ ç¹ãæããã ããã«ã¯æ害æåã«èŠªåæ§ãæããååç©ïŒã
ããããªã¬ã³ãïŒãåºå®ãããããããã¢ãã€ã
ãã€ãŒã¯ãããã°ã©ãã®åçã«ããåžçäœãè©Šã¿
ãããŠãããããã«çšãããªã¬ã³ãã¯æ¯èŒçå®äŸ¡
ã§ãéžææ§ãæ¯èŒçãã奜éœåã§ããããæ äœã«
ã¢ã¬ããŒã¹ã«ä»£è¡šããããœããã²ã«ãçšããŠãã
ãããã«ã©ã ã«å å¡«ããå Žåã«ååãªæµéãåŸã
ã®ãå°é£ã§ãã€ããããªãã¡è¿å¹Žçºéããäœå€åŸª
ç°åè·¯ãçšããè¡æ¶²ãè¡æŒ¿ããæµçæ³ïŒãããã
ãã©ãºãããšã¬ãŒã·ã¹çïŒã«ãããã®åžçäœãçš
ããããšããã°ãé«æµéãåŸãããã«ã«ã©ã 圢ç¶
ã«ç¹å¥ã®å·¥å€«ãèŠãããŸããã°ãã°è©°ããçãã
ããäºåã®ã«ã©ã ãçšæããŠããå¿ èŠããããªã©
åé¡ç¹ãå€ããå®å®ããŠæ²»çãè¡ãªããç¶æ³ã«ã¯
å°ã€ãŠããªããåžçäœã®æµãç¹æ§ãåäžãããã
ãã«ã¯æ©æ¢°åŒ·åºŠã®å€§ããæ äœãçšããã°ããã®ã¯
æçœã§ãããããããã®æ äœãçšãããšã¢ã¬ããŒ
ã¹çã®ãœããã²ã«ã«æ¯ã¹ãŠåžçèœåãäœäžããã
ãšãç¥ãããŠããã äžæ¹ãç¡«é žåå€ç³çã®ããªã¢ããªã³ååç©ããª
ãèçœãšèŠªåæ§ãæã¡ãéå±ã€ãªã³ã®å ±åäžã§æ²
殿ã圢æããããšãç¥ãããŠãããäŸãã°M.
Burnstein and H.R.ScholnickïŒAdv.in Lipid.
Res.ïŒ11ïŒ67ïŒ1973ïŒããèšåºåæçã«çšããã
ãŠããããããªãããã®æ¹æ³ã§æ£è ã®è¡äžãã
LDLãé€å»ããããšããã°ãåŠçããããšãã
è¡æŒ¿ã«å¯Ÿãå°ããšã0.05ïŒ ã®ããªã¢ããªã³ååç©
ããã³0.02Mäžã®éå±ã€ãªã³ãæ·»å ããªããã°ãª
ããããŸãçããæ²æ®¿ãé å¿åé¢çã®æ¹æ³ã§åé¢
ããå¿ èŠãçããæäœãç ©éã§å±éºæ§ãé«ããäº
å®äžé©çšäžå¯èœã§ãã€ãã æ¬çºæè ãã¯éæç 究ã®çµæãç¹å®ã®ããŒã©ã¹
ããªããŒããŒãã²ã«ãçšããããã«ãªãèçœã«èŠª
åæ§ãæããããªã¢ããªã³ååç©ãåºå®ããããš
ã«ãããå®äŸ¡ã§æµãç¹æ§ãããããã€ãœããã²ã«
ãæ äœã«çšããå Žåã«æ¯ãåžçèœåãäœäžããªã
é€å»èœåã«åªãããªãèåžçäœãåŸãæ¬çºæã«å°
éããã ããªãã¡æ¬çºæã¯ãçç¶èçœè³ªã®æé€éçåå
éã100äžä»¥äžïŒåªä»¥äžã®ããŒã©ã¹ããªããŒããŒ
ãã²ã«ã«ããªãèçœã«èŠªåæ§ãæããããªã¢ããª
ã³ååç©ãåºå®ããŠãªããªãèçœåžçäœã§ããã 以äžè©³çŽ°ã«æ¬çºæã説æããã æ¬çºæã«çšããã«é©ããæ äœã¯ãïŒïŒèå§æ§ã§
ããããšãïŒïŒæ¯èŒç倧ããªåŸã®çŽ°åãæããã
ãšãå¿ èŠã§ãããããªããŒããŒãã²ã«ã¯æ¬çºæã«
æãé©ããæ äœã§ããã ããã§ããããŒãã²ã«ãšã¯ãããã¹ãã©ã³ãã¢
ã¬ããŒã¹ãã¢ã¯ãªã«ã¢ããçã®ãœããã²ã«ã«æ¯ã¹
溶åªã«ããèšæœ€ãå°ãªãããŸãå§åã«ããå€åœ¢ã
ã«ããã²ã«ã®ããšããããããŒãã²ã«ãšãœããã²
ã«ã¯æ¬¡ã®æ¹æ³ã«ããåºå¥ããããšãã§ãããããª
ãã¡åŸèšåèäŸã«ç€ºããããšãã²ã«ãåçç¶ã«ã©
ã ã«åäžã«å å¡«ããæ°Žæ§æ¶²äœãæµããéã®å§åæ
倱ãšæµéã®é¢ä¿ããããŒãã²ã«ã§ã¯ã»ãŒçŽç·ãšãª
ãã®ã«å¯Ÿãããœããã²ã«ã§ã¯å§åãããç¹ãè¶ã
ããšã²ã«ãå€åœ¢ãå§å¯åããŠæµéãå¢å ããªããª
ããæ¬çºæã§ã¯ãåŸèšåèäŸã«ç€ºããã«ã©ã ãçš
ããå Žåãå°ããšã0.3KgïŒcm2ãŸã§äžèšçŽç·é¢ä¿
ã®ãããã®ãããŒãã²ã«ãšç§°ããã 次ã«èŠæ±ãããæ§è³ªã¯æ¯èŒç倧ããªåŸã®çŽ°åã
æããããšã§ãããããªãã¡LDLã¯ååéãå°
ããšã100äžä»¥äžãšãããã巚倧ååã§ãããã
ããåžçé€å»ããããã«ã¯LDLã现åå ã«äŸµå ¥
ã§ããããšãå¿ èŠã§ããã 次ã«LDLã现åå ã«äŸµå ¥ã§ããŠãã现åå ã«
äŸµå ¥ãã確çãããçšåºŠå€§ãããªããã°åžçäœãš
ããŠã®æ§èœã¯äœããããªãã¡ç§»åçžãšåºå®çžïŒçŽ°
åå ïŒéã®åé æ¯ïŒåºå®çžã®æ¿åºŠïŒç§»åçžã®æ¿
床ïŒã倧ããã»ã©å¥œãŸãããšèãããããåŸã€ãŠ
现ååŸã倧ããçšæå©ãšæãããã 现ååŸã®æž¬å®æ³ã«ã¯çš®ã ãããæ°Žéå§å ¥æ³ãæ
ãããçšããããŠããããããªããŒããŒãã²ã«ã®
å Žåã«ã¯é©çšã§ããªãããšãããããããã€ãŠçŽ°
ååŸã®ç®å®ãšããŠæé€éçååéãçšããã®ãé©
åœã§ãããæé€éçååéãšã¯ææžïŒäŸãã°æ³¢å€
éåè¡ãè±äºä¿åœŠèãå®éšé«é液äœã¯ãããã°ã©
ããååŠå人ïŒçã«è¿°ã¹ãããŠããããšããã²ã«
浞éã¯ãããã°ã©ãã€ãŒã«ãããŠçŽ°åå ã«äŸµå ¥ã§
ããªãïŒæé€ãããïŒååã®ãã¡æãå°ããåå
éããã€ãã®ã®ååéããããçŸè±¡çã«ã¯ãæé€
éçååé以äžã®ååã¯ç§»åçžäœç©Voè¿åã«æº¶
åºãããããšãããçš®ã ã®ååéã®ååç©ãçšã
ãŠæº¶åºäœç©ãšã®é¢ä¿ã調ã¹ãã°æé€éçååéã
æ±ããããšãã§ãããæé€éçååéã¯å¯Ÿè±¡ãšã
ãååç©ã®çš®é¡ã«ããç°ãªãããšãç¥ãããŠã
ããäžè¬ã«çç¶èçœè³ªãããã¹ãã©ã³ãããªãšã
ã¬ã³ã°ãªã³ãŒã«çã«ã€ããŠãã調ã¹ãããŠãã
ãããªãèçœã«ã€ããŠã¯ã»ãšãã©èª¿ã¹ãããŠããª
ããåŸã€ãŠæãé¡äŒŒããŠããçç¶èçœè³ªïŒããŒã«
ã¹ãå«ãïŒãçšããŠåŸãããå€ãçšããã®ãé©åœ
ã§ããã æé€éçã®ç°ãªãçš®ã ã®æ äœãçšããŠæ€èšãã
çµæãäºæ³ã«åãæé€éçååéãLDLã®åå
éããå°ãã100äžçšåºŠã®ãã®ã§ãããçšåºŠã®
LDLåžçèœã瀺ãããŸã现ååŸã®å€§ãããã®çš
èœåã倧ããããã§ã¯ãªãããããLDL以å€ã®
èçœãé€å»ãããããšããæé©ãªçŽ°ååŸã®ç¯å²ã
ååšããããšãæããã«ãªã€ããããªãã¡100äž
æªæºã®æé€éçååéãæã€æ äœãçšããå Žåã¯
LDLã®é€å»éã¯å°ããå®çšã«èããªãããæé€
éçååéã100äžä¹è³æ°çŸäžãšLDLã®ååéã«
è¿ãæ äœã§ãããçšåºŠå®çšã«äŸãããåžçäœãåŸ
ããããäžæ¹æé€éçååéãšLDLã®åžçéã
ããã³LDL以å€ã®èçœè³ªã®åžçïŒããããéç¹
ç°åžçïŒãšã®é¢ä¿ã調ã¹ããšãæé€éçååéã
倧ãããªãã«ã€ãLDLã®åžçéãå¢å ãããã
ãã®å¢å ã¯æé€éçã1000äžãè¶ ãããšé æã¡ãš
ãªããäžæ¹LDL以å€ã®èçœãäŸãã°IGGãIGMç
ã®åžçãç®ç«ã€ããã«ãªãããšãããã€ãããã
ã«æé€éçååéãïŒå以äžã«ãªããšãªã¬ã³ãã®
åºå®åéãæžå°ããŠçµæçã«LDLã®åžçéãæž
ããéç¹ç°åžçãç¡èŠã§ããªããªããåŸã€ãŠæ¬çº
æã«çšããæ äœã®å¥œãŸããæé€éçååéã¯100
äžä»¥äžïŒå以äžã§ãããæã奜ãŸããã¯300äžä»¥
äž7000äžä»¥äžã§ããã 次ã«æ äœã®å€åæ§é ã«ã€ããŠã¯è¡šé¢å€åæ§ãã
ãå šå€åæ§ã奜ãŸããã空å容ç©ã20ïŒ ä»¥äžã§ã
ãããšã奜ãŸãããæ äœã®åœ¢ç¶ã¯ãç²ç¶ãç¹ç¶
ç¶ãèç¶ããããŒãã¢ã€ããŒç¶çä»»æã®åœ¢ç¶ãéž
ã¶ããšãã§ãããç²åç¶ã®æ äœãçšããå Žåãã
ã®ç²ååŸã¯ïŒÎŒä»¥äž5000Ό以äžã§ããã®ãæãŸã
ãã ããã«æ äœè¡šé¢ã«ã¯åºå®ååå¿ã«çšãåŸãå®èœ
åºãããã¯å®¹æã«æŽ»æ§åãåŸãå®èœåºãååšããŠ
ãããšå¥œéœåã§ããããããã®å®èœåºã®ä»£è¡šäŸãš
ããŠã¯ãã¢ããåºãã«ã«ããã·ã«åºãããããã·
ã«åºãããªãŒã«åºãé žç¡æ°Žç©åºããµã¯ã·ãã«ã€ã
ãåºãå¡©çŽ åºãã¢ã«ãããåºãã¢ããåºããšãã
ã·åºçããããããã æ¬çºæã«é©ããããªããŒããŒãã²ã«ã®ä»£è¡šäŸãš
ããŠã¯ãã¹ãã¬ã³âãžããã«ãã³ãŒã³å ±éåäœã
æ¶æ©ããªããã«ã¢ã«ã³ãŒã«ãæ¶æ©ããªã¢ã¯ãªã¬ãŒ
ããæ¶æ©ãããããã«ãšãŒãã«âç¡æ°Žãã¬ã€ã³é ž
å ±éåäœãæ¶æ©ãããã¹ãã¬ã³âç¡æ°Žãã¬ã€ã³é ž
å ±éåäœãæ¶æ©ããªã¢ããçã®åæé«ååãå€å
質ã»ã«ããŒã¹ã²ã«çã®ç¡¬è³ªå€åäœãããã³ããã
ã®è¡šé¢ã«å€ç³é¡ãåæé«ååçãã³ãŒãã€ã³ã°ã
ããã®çãããããããããããã«éå®ãããã
ãã§ã¯ãªãããããã®ããªããŒããŒãã²ã«ã¯åç¬
ã§çšããŠããããïŒçš®é¡ä»¥äžæ··åããŠçšããŠãã
ãã æ¬çºæã«çšããã«é©ãããªãèçœã«èŠªåæ§ãæ
ããããªã¢ããªã³ååç©ã®ä»£è¡šäŸãšããŠã¯ããã
ãªã³ãããã¹ãã©ã³ç¡«é žãã³ã³ããã€ãã³ç¡«é žã
ã³ã³ããã€ãã³ããªç¡«é žãããã©ã³é žãã±ã©ã¿ã³
ç¡«é žããããªãã³ç¡«é žããã·ã©ã³ç¡«é žãã«ããã³
ç¡«é žãã»ã«ããŒã¹ç¡«é žãããã³ç¡«é žããããµã³ç¡«
é žããã¯ãã³ç¡«é žãã€ããªã³ç¡«é žãã¢ã«ã®ã³é žç¡«
é žãã°ãªã³ãŒã²ã³ç¡«é žãããªã©ã¯ããŒã¹ç¡«é žãã«
ã©ã²ãã³ç¡«é žããã³ãã³ç¡«é žãããªã°ã«ã³ãŒã¹ç¡«
é žãã©ãããªã³ç¡«é žãã¬ã©ã¯ã¿ã³ç¡«é žãã¬ãã³ç¡«
é žãã¡ããµã«ããšãŒãçã®ç¡«é žåå€ç³ããªã³ã¿ã³
ã°ã¹ãã³é žãããªç¡«é žåã¢ãããŒã«ãããªããã«
ã¢ã«ã³ãŒã«ç¡«é žãããªãªã³é žçãããããããæ
ã奜ãŸããäŸãšããŠã¯ããããªã³ãããã¹ãã©ã³
ç¡«é žãã³ã³ããã€ãã³ããªç¡«é žããããããã ãªãèçœã«èŠªåæ§ãæããååç©ïŒãªã¬ã³ãïŒ
ãæ äœã«åºå®ããæ¹æ³ãšããŠã¯æ¢ç¥ã®çš®ã ã®æ¹æ³
ãçšããããšãã§ãããããªãã¡ç©ççåžçæ³ã
ã€ãªã³çµåæ³ãå ±æçµåæ³çã§ãããæ¬çºæã«ã
ãåžçäœãæ²»çã«çšããã«ã¯ãæ» èæãããã¯æ²»
çäžã«ãªã¬ã³ããè±é¢ããªãããšãéèŠã§ããã®
ã§çµåã®åŒ·åºãªå ±æçµåæ³ãæãŸãããã€ãªã³çµ
åæ³ãçšããã«ããŠããªã¬ã³ããå ±æçµåçã«æ¶
æ©ããŠããããšãæãŸããããŸãå¿ èŠã«ããã¹ã
ãŒãµãŒãæ äœãšãªã¬ã³ãã®éã«å°å ¥ããŠãããã ãªã¬ã³ãã®åºå®åéã«ã€ããŠã¯ããªã¬ã³ãã®æ§
ç¶ã掻æ§ã«ããç°ãªãããææã®ãªãèçœåžçé
ãåŸãã«ã¯ã«ã©ã äœç©ïŒmlããã0.02mg以äžã奜
ãŸããããŸãçµæžæ§ãèæ ®ãããš100mg以äžãæ
ãŸãããããã«å¥œãŸããã¯ã«ã©ã äœç©ïŒmlããã
0.5mg以äž20mg以äžã§ããã æ¬çºæã«ããåžçäœãæ²»çã«çšããã«ã¯çš®ã ã®
æ¹æ³ããããæã簡䟿ãªæ¹æ³ãšããŠã¯æ£è ã®è¡æ¶²
ãäœå€ã«å°åºããŠè¡æ¶²ããã°çã«è²¯ããããã«æ¬
çºæã®åžçäœïŒç²åïŒãæ··åããŠLDLãé€å»ã
ãåŸããã€ã«ã¿ãŒãéããŠåžçäœïŒç²åïŒãé€å»
ãè¡æ¶²ãæ£è ã«æ»ãæ¹æ³ãããããã®æ¹æ³ã¯è€é
ãªè£ 眮ãå¿ èŠãšããªãããïŒåã®åŠçéãå°ãªã
æ²»çã«æéãèŠããæäœãç ©éã«ãªããšããæ¬ ç¹
ãæããã次ã®æ¹æ³ã¯åžçäœãã«ã©ã ã«å å¡«ãã
äœå€åŸªç°åè·¯ã«çµã¿èŸŒã¿ãªã³ã©ã€ã³ã§åžçé€å»ã
è¡ãªããã®ã§ãããåŠçæ¹æ³ã«ã¯å šè¡ãçŽæ¥ãã
æµããæ¹æ³ãšãè¡æ¶²ããè¡æŒ¿ãåé¢ããåŸãè¡æŒ¿
ãã«ã©ã ã«éãæ¹æ³ããããæ¬çºæã«ããåžçäœ
ã¯ããããã®æ¹æ³ã«ãçšããããšãã§ããããå
è¿°ã®ããšããªã³ã©ã€ã³åŠçã«æãé©ããŠããã æ¬çºæã«ããåžçäœãçšããŠLDLãé€å»ãã
éãåŠçããããšããè¡æ¶²ããããã¯è¡æŒ¿ã«å€äŸ¡
éå±ã€ãªã³ãæ·»å ããããšã«ããé€å»å¹çãéžæ
æ§ãåäžãããããšãå¯èœã§ããããã®ç®çã«çš
ããå€äŸ¡éå±ã€ãªã³ãšããŠã¯ãã«ã«ã·ãŠã ããã°
ãã·ãŠã ãããªãŠã ãã¹ããã³ããŠã çã®ã¢ã«ã«
ãªåé¡éå±ã€ãªã³ãã¢ã«ãããŠã çã®å±å çŽ ã€
ãªã³ããã³ã¬ã³çã®å±å çŽ ã€ãªã³ãã³ãã«ãç
ã®å±å çŽ ã€ãªã³çããããããã 以äžå®æœäŸã«ããæ¬çºæãããã«è©³ãã説æã
ãã åèäŸ äž¡ç«¯ã«ååŸ15ÎŒïœã®ãã€ã«ã¿ãŒãè£ çããã¬ã©
ã¹è£œåçã«ã©ã ïŒå åŸïŒmmãã«ã©ã é·150mmïŒã«
ã¢ã¬ããŒã¹ã²ã«ïŒBiorad瀟補Biogel A5mãç²åŸ
50ã100ã¡ãã·ãŠïŒãããªããŒããŒãã²ã«ïŒæ±æŽæ¹
éå·¥æ¥(æ ª)補ããšããŒã«HW65ãç²åŸ50ã100ÎŒ
ïœãããã³ãããœ(æ ª)補ã»ã«ããã¢ã€ã³GCâ700ã
ç²åŸ45ã105ÎŒïœïŒãããããåäžã«å å¡«ããã
ãªã¹ã¿ãã€ãã¯ãã³ãã«ããæ°Žãæµããæµéãšå§
åæ倱ã®é¢ä¿ãæ±ãããçµæãå³ïŒã«ç€ºãããã
ã«ãããšããªããŒããŒãã²ã«ãå§åã®å¢å ã«ã»ãŒ
æ¯äŸããŠæµéãå¢å ããã®ã«å¯Ÿããã¢ã¬ããŒã¹ã²
ã«ã¯å§å¯åãã²ããããå§åãå¢å ãããŠãæµé
ãå¢å ããªãããšã瀺ããŠããã å®æœäŸ ïŒ æ¶æ©ã¢ã¯ãªã¬ãŒãã²ã«ïŒå šå€åæ§ã®ããŒãã²
ã«ïŒã§ããããšããŒã«HW55ïŒçç¶èçœè³ªã®æé€
éçååéïŒä»¥äžèçœè³ªã®æé€éçãšç¥ç§°ããïŒ
700000ãç²åŸã50ã100ÎŒïœïŒãHW60ïŒèçœè³ªã®
æé€éç1000000ãç²åŸ50ã100ÎŒïœïŒãHW65
ïŒèçœè³ªã®æé€éç5000000ãç²åŸ50ã100ÎŒïœïŒã
HW75ïŒèçœè³ªã®æé€éç50000000ãç²åŸ50ã
100ÎŒïœïŒå10mlã«é£œåNaOH氎溶液ïŒmlããšã
ã¯ãã«ãããªã³15mlãå ãæ¹æããªãã50âã§ïŒ
æéåå¿ããšããã·åã²ã«ãåŸãããã®ã²ã«ã«æ¿
ã¢ã³ã¢ãã¢æ°Ž20mlãå ã50âã§ïŒæéæ¹æãã¢ã
ãåºãå°å ¥ããã 次ã«ãããªã³200mgã10mlã®æ°Žã«æº¶è§£ãPH4.5ã«
調æŽããåŸãããã«ïŒmlã®äžèšã¢ããåºå«æã²ã«
ãå ãããããã«ïŒâãšãã«âïŒâïŒãžã¡ãã«ã¢
ãããããã«ïŒâã«ã«ããžã€ãã200mgãPHã4.5
ã«ä¿ã¡ãªããæ·»å ãïŒâã§24æéæ¯ãšããããå
å¿çµäºåŸãïŒã¢ã«é£å¡©æº¶æ¶²ã0.5ã¢ã«é£å¡©æº¶æ¶²ã
æ°Žã§æŽæµããããªã³åºå®åã²ã«ãåŸããåºå®åã
ãããããªã³ã®éã¯ãããã2.2mgïŒmlã1.8mgïŒ
mlã1.4mgïŒmlã0.8mgïŒmlã§ãã€ãã å®æœäŸ ïŒ ç¡¬è³ªã»ã«ããŒã¹å€åäœïŒå šå€åæ§ã®ããŒãã²
ã«ïŒãã»ã«ããã¢ã€ã³GC700ïŒãããœ(æ ª)補ãèçœ
質ã®æé€éç400000ãç²åŸ45ã105ÎŒïœïŒãã»ã«ã
ãã¢ã€ã³ïŒ¡âïŒïŒãããœ(æ ª)補ïŒè©ŠäœåïŒãèçœè³ª
ã®æé€éç700000ãç²åŸ45ã105ÎŒïœïŒãã»ã«ãã
ã¢ã€ã³ïŒ¡âïŒïŒãããœ(æ ª)補ïŒè©ŠäœåïŒãèçœè³ªã®
æé€éççŽ50000000ãç²åŸ45ã105ÎŒïœïŒããã
ããåžåŒéããå10gããšããããã«20ïŒ
NaOHã4gãããã¿ã³12gãå ããããã«ãããª
ã³ç³»çé¢æŽ»æ§å€TWEEN20ãïŒæ»Žå ãæ¹æããŠã²
ã«ãåæ£ãããã40âã§ïŒæéæ¹æåŸãããã«ãš
ãã¯ãã«ãããªã³5gãå ã40âã§ïŒæéæ¹æã
ããé眮åŸãäžæŸã¿ãæšãŠãã²ã«ãæ°ŽæŽéããŠ
ãšããã·åã²ã«ãåŸããããã«15mlã®æ¿ã¢ã³ã¢ã
ã¢æ°Žãå ã40âã§1.5æéæ¹æããå 容ç©ãåžåŒ
éãæ°ŽæŽããŠã¢ããåºã®å°å ¥ãããã»ã«ããŒã¹
ã²ã«ãåŸãã 次ã«ãããªã³200mgã10mlã®æ°Žã«æº¶è§£ãããã
ã«äžèšã¢ããåºå«æã²ã«ïŒmlãå ããŠPH4.5ã«èª¿
æŽãããããã«ïŒâãšãã«âïŒâïŒãžã¡ãã«ã¢ã
ããããã«ïŒâã«ã«ããžã€ãã200mgãPH4.5ã«ä¿
ã¡ãªããæ·»å ããïŒâã§24æéæ¯ãšããããåå¿
çµäºåŸãïŒã¢ã«é£å¡©æº¶æ¶²ã0.5ã¢ã«é£å¡©æº¶æ¶²ãæ°Ž
ã§æŽæµããããªã³åºå®åã²ã«ãåŸããåºå®åãã
ããããªã³éã¯ãããã2.5mgïŒmlã2.2mgïŒmlã
1.8mgïŒmlã§ãã€ãã å®æœäŸ ïŒ ãããªã³ãã³ã³ããã€ãã³ããªç¡«é žã«ãããä»
ã¯å®æœäŸïŒãšåãæ¹æ³ã§ã³ã³ããã€ãã³ããªç¡«é ž
åºå®åããšããŒã«ã²ã«HW65ãåŸããåºå®åéã¯
1.2mgïŒmlã§ãã€ãã å®æœäŸ ïŒ ã»ã«ããã¢ã€ã³ïŒ¡âïŒ ïŒmlã«0.5ã¢ã«NaIO4
ãå ããŠ10mlãšãïŒæé宀枩ã§æ¹æåŸãéæ°ŽæŽ
ããŠã¢ã«ãããåºãå°å ¥ããã次ã«ãã®ã²ã«ãPH
ïŒã®ãªã³é žç·©è¡æ¶²10mläžã«æžæ¿ãããžãšãã«ã¢ã
ã³50mgãå ããŠå®€æž©ã§20æéæ¹æãå¥ãããã
ããïŒïŒ NaBH4溶液10mläžã«æžæ¿ã15åééå
åŸãéãæŽæµããŠã¢ããåºãå°å ¥ããã 次ã«ããã¹ãã©ã³ç¡«é ž300mgã0.25ã¢ã«NaIO4
溶液10mlã«æº¶è§£ã宀枩ã§ïŒæéæ¹æåŸããšãã¬ã³
ã°ãªã³ãŒã«200mgãå ããŠïŒæéæ¹æããããã®
溶液ãPHïŒã«èª¿æŽããåŸãäžèšã¢ããåºå«æã²ã«
ãæžæ¿ã24æéæ¹æãããåå¿çµäºåŸãã²ã«ã
éãæ°ŽæŽãããããïŒïŒ NaBH4溶液10mlã«æžæ¿
ã15åééå ããéæ°ŽæŽããŠããã¹ãã©ã³ç¡«é ž
åºå®åã»ã«ããŒã¹ã²ã«ãåŸããåºå®åéã¯0.5
mgïŒmlã§ãã€ãã å®æœäŸ ïŒ å®æœäŸïŒãïŒã§åæããåžçäœåïŒmlãè©Šéšç®¡
ã«ãšããããã«äººè¡æŒ¿ïŒmlïŒCaCl20.02Må«æïŒ
ãå ããŠæ¹æãã20âã§15åéé眮åŸãäžæŸã¿ã®
ã³ã¬ã¹ãããŒã«æ¿åºŠããã³LDLïŒÎ²âãªãè
çœïŒéã枬å®ãããçµæãè¡šïŒã«ç€ºãã
é¢ãããããã«è©³ããã¯ãè¡æ¶²ãããã¯è¡æŒ¿ãè¡
æž äžãããªãèçœãç¹ã«äœå¯åºŠãªãèçœ
ïŒLDLïŒãéžæçã«åžçé€å»ããããã®åžçäœã«
é¢ããã è¡æ¶²äžã«ååšãããªãèçœã®ãã¡LDLã¯ã³ã¬
ã¹ãããŒã«ãå€ãå«ã¿ãåè硬åã®åå ãšãªãã
ãšãç¥ãããŠããããšããã家ææ§é«èè¡ççã®
é«ã³ã¬ã¹ãããŒã«çã§ã¯æ£åžžå€ã®æ°åã®LDLå€
ã瀺ããå åèã®ç¡¬åçãã²ããããããã®æ²»ç
ã®ãããè¡äžLDLã®äœäžãç®çãšããŠé£äºç
æ³ããããã³ãŒã«ãã³ã¬ã¹ãã©ãã³çã®è¬ç©çæ³
ãè¡ãªãããŠãããå¹æã«é床ããããå¯äœçšã
æžå¿µãããŠãããç¹ã«å®¶ææ§é«èè¡çã«å¯ŸããŠã¯
æ£è ã®è¡æŒ¿ãåé¢ããåŸãæ£åžžè¡æŒ¿ãããã¯ã¢ã«
ããã³çãæåãšããè£æ¶²ãšäº€æããããããã
è¡æŒ¿äº€æçæ³ãçŸåšã®ãšããã»ãŒå¯äžã®å¹æçãª
æ²»çæ³ã§ãããããããªããåšç¥ã®ããšãè¡æŒ¿äº€
æçæ³ã¯ãïŒïŒé«äŸ¡ãªæ°é®®è¡æŒ¿ãããã¯è¡æŒ¿è£œå€
ãçšããå¿ èŠããããïŒïŒèçããŒã«ã¹çã®ææ
ã®ãããããããïŒïŒæ害æåã®ã¿ã§ãªãæçšæ
åãåæã«é€å»ããŠããŸãçã®æ¬ ç¹ãæãããã
ããã®æ¬ ç¹ã解æ¶ããç®çã§èã«ããæ害æåã®
é€å»ãè©Šã¿ãããŠããããéžææ§ã®ç¹ã§æºè¶³ã§ã
ããã®ã¯ããŸã åŸãããŠããªãã ãŸãåãç®çã§æåãæäœçãåºå®ããããã
ãå ç«åžçäœãçšããè©Šã¿ããªãããŠããããã
ã¯éžææ§ã®ç¹ã§ã¯ã»ãŒæºè¶³ã§ãããã®ã®ãçšãã
æåãæäœã®å ¥æãå°é£ãã€é«äŸ¡ã§ãããšããèŽ
åœçãªæ¬ ç¹ãæããã ããã«ã¯æ害æåã«èŠªåæ§ãæããååç©ïŒã
ããããªã¬ã³ãïŒãåºå®ãããããããã¢ãã€ã
ãã€ãŒã¯ãããã°ã©ãã®åçã«ããåžçäœãè©Šã¿
ãããŠãããããã«çšãããªã¬ã³ãã¯æ¯èŒçå®äŸ¡
ã§ãéžææ§ãæ¯èŒçãã奜éœåã§ããããæ äœã«
ã¢ã¬ããŒã¹ã«ä»£è¡šããããœããã²ã«ãçšããŠãã
ãããã«ã©ã ã«å å¡«ããå Žåã«ååãªæµéãåŸã
ã®ãå°é£ã§ãã€ããããªãã¡è¿å¹Žçºéããäœå€åŸª
ç°åè·¯ãçšããè¡æ¶²ãè¡æŒ¿ããæµçæ³ïŒãããã
ãã©ãºãããšã¬ãŒã·ã¹çïŒã«ãããã®åžçäœãçš
ããããšããã°ãé«æµéãåŸãããã«ã«ã©ã 圢ç¶
ã«ç¹å¥ã®å·¥å€«ãèŠãããŸããã°ãã°è©°ããçãã
ããäºåã®ã«ã©ã ãçšæããŠããå¿ èŠããããªã©
åé¡ç¹ãå€ããå®å®ããŠæ²»çãè¡ãªããç¶æ³ã«ã¯
å°ã€ãŠããªããåžçäœã®æµãç¹æ§ãåäžãããã
ãã«ã¯æ©æ¢°åŒ·åºŠã®å€§ããæ äœãçšããã°ããã®ã¯
æçœã§ãããããããã®æ äœãçšãããšã¢ã¬ããŒ
ã¹çã®ãœããã²ã«ã«æ¯ã¹ãŠåžçèœåãäœäžããã
ãšãç¥ãããŠããã äžæ¹ãç¡«é žåå€ç³çã®ããªã¢ããªã³ååç©ããª
ãèçœãšèŠªåæ§ãæã¡ãéå±ã€ãªã³ã®å ±åäžã§æ²
殿ã圢æããããšãç¥ãããŠãããäŸãã°M.
Burnstein and H.R.ScholnickïŒAdv.in Lipid.
Res.ïŒ11ïŒ67ïŒ1973ïŒããèšåºåæçã«çšããã
ãŠããããããªãããã®æ¹æ³ã§æ£è ã®è¡äžãã
LDLãé€å»ããããšããã°ãåŠçããããšãã
è¡æŒ¿ã«å¯Ÿãå°ããšã0.05ïŒ ã®ããªã¢ããªã³ååç©
ããã³0.02Mäžã®éå±ã€ãªã³ãæ·»å ããªããã°ãª
ããããŸãçããæ²æ®¿ãé å¿åé¢çã®æ¹æ³ã§åé¢
ããå¿ èŠãçããæäœãç ©éã§å±éºæ§ãé«ããäº
å®äžé©çšäžå¯èœã§ãã€ãã æ¬çºæè ãã¯éæç 究ã®çµæãç¹å®ã®ããŒã©ã¹
ããªããŒããŒãã²ã«ãçšããããã«ãªãèçœã«èŠª
åæ§ãæããããªã¢ããªã³ååç©ãåºå®ããããš
ã«ãããå®äŸ¡ã§æµãç¹æ§ãããããã€ãœããã²ã«
ãæ äœã«çšããå Žåã«æ¯ãåžçèœåãäœäžããªã
é€å»èœåã«åªãããªãèåžçäœãåŸãæ¬çºæã«å°
éããã ããªãã¡æ¬çºæã¯ãçç¶èçœè³ªã®æé€éçåå
éã100äžä»¥äžïŒåªä»¥äžã®ããŒã©ã¹ããªããŒããŒ
ãã²ã«ã«ããªãèçœã«èŠªåæ§ãæããããªã¢ããª
ã³ååç©ãåºå®ããŠãªããªãèçœåžçäœã§ããã 以äžè©³çŽ°ã«æ¬çºæã説æããã æ¬çºæã«çšããã«é©ããæ äœã¯ãïŒïŒèå§æ§ã§
ããããšãïŒïŒæ¯èŒç倧ããªåŸã®çŽ°åãæããã
ãšãå¿ èŠã§ãããããªããŒããŒãã²ã«ã¯æ¬çºæã«
æãé©ããæ äœã§ããã ããã§ããããŒãã²ã«ãšã¯ãããã¹ãã©ã³ãã¢
ã¬ããŒã¹ãã¢ã¯ãªã«ã¢ããçã®ãœããã²ã«ã«æ¯ã¹
溶åªã«ããèšæœ€ãå°ãªãããŸãå§åã«ããå€åœ¢ã
ã«ããã²ã«ã®ããšããããããŒãã²ã«ãšãœããã²
ã«ã¯æ¬¡ã®æ¹æ³ã«ããåºå¥ããããšãã§ãããããª
ãã¡åŸèšåèäŸã«ç€ºããããšãã²ã«ãåçç¶ã«ã©
ã ã«åäžã«å å¡«ããæ°Žæ§æ¶²äœãæµããéã®å§åæ
倱ãšæµéã®é¢ä¿ããããŒãã²ã«ã§ã¯ã»ãŒçŽç·ãšãª
ãã®ã«å¯Ÿãããœããã²ã«ã§ã¯å§åãããç¹ãè¶ã
ããšã²ã«ãå€åœ¢ãå§å¯åããŠæµéãå¢å ããªããª
ããæ¬çºæã§ã¯ãåŸèšåèäŸã«ç€ºããã«ã©ã ãçš
ããå Žåãå°ããšã0.3KgïŒcm2ãŸã§äžèšçŽç·é¢ä¿
ã®ãããã®ãããŒãã²ã«ãšç§°ããã 次ã«èŠæ±ãããæ§è³ªã¯æ¯èŒç倧ããªåŸã®çŽ°åã
æããããšã§ãããããªãã¡LDLã¯ååéãå°
ããšã100äžä»¥äžãšãããã巚倧ååã§ãããã
ããåžçé€å»ããããã«ã¯LDLã现åå ã«äŸµå ¥
ã§ããããšãå¿ èŠã§ããã 次ã«LDLã现åå ã«äŸµå ¥ã§ããŠãã现åå ã«
äŸµå ¥ãã確çãããçšåºŠå€§ãããªããã°åžçäœãš
ããŠã®æ§èœã¯äœããããªãã¡ç§»åçžãšåºå®çžïŒçŽ°
åå ïŒéã®åé æ¯ïŒåºå®çžã®æ¿åºŠïŒç§»åçžã®æ¿
床ïŒã倧ããã»ã©å¥œãŸãããšèãããããåŸã€ãŠ
现ååŸã倧ããçšæå©ãšæãããã 现ååŸã®æž¬å®æ³ã«ã¯çš®ã ãããæ°Žéå§å ¥æ³ãæ
ãããçšããããŠããããããªããŒããŒãã²ã«ã®
å Žåã«ã¯é©çšã§ããªãããšãããããããã€ãŠçŽ°
ååŸã®ç®å®ãšããŠæé€éçååéãçšããã®ãé©
åœã§ãããæé€éçååéãšã¯ææžïŒäŸãã°æ³¢å€
éåè¡ãè±äºä¿åœŠèãå®éšé«é液äœã¯ãããã°ã©
ããååŠå人ïŒçã«è¿°ã¹ãããŠããããšããã²ã«
浞éã¯ãããã°ã©ãã€ãŒã«ãããŠçŽ°åå ã«äŸµå ¥ã§
ããªãïŒæé€ãããïŒååã®ãã¡æãå°ããåå
éããã€ãã®ã®ååéããããçŸè±¡çã«ã¯ãæé€
éçååé以äžã®ååã¯ç§»åçžäœç©Voè¿åã«æº¶
åºãããããšãããçš®ã ã®ååéã®ååç©ãçšã
ãŠæº¶åºäœç©ãšã®é¢ä¿ã調ã¹ãã°æé€éçååéã
æ±ããããšãã§ãããæé€éçååéã¯å¯Ÿè±¡ãšã
ãååç©ã®çš®é¡ã«ããç°ãªãããšãç¥ãããŠã
ããäžè¬ã«çç¶èçœè³ªãããã¹ãã©ã³ãããªãšã
ã¬ã³ã°ãªã³ãŒã«çã«ã€ããŠãã調ã¹ãããŠãã
ãããªãèçœã«ã€ããŠã¯ã»ãšãã©èª¿ã¹ãããŠããª
ããåŸã€ãŠæãé¡äŒŒããŠããçç¶èçœè³ªïŒããŒã«
ã¹ãå«ãïŒãçšããŠåŸãããå€ãçšããã®ãé©åœ
ã§ããã æé€éçã®ç°ãªãçš®ã ã®æ äœãçšããŠæ€èšãã
çµæãäºæ³ã«åãæé€éçååéãLDLã®åå
éããå°ãã100äžçšåºŠã®ãã®ã§ãããçšåºŠã®
LDLåžçèœã瀺ãããŸã现ååŸã®å€§ãããã®çš
èœåã倧ããããã§ã¯ãªãããããLDL以å€ã®
èçœãé€å»ãããããšããæé©ãªçŽ°ååŸã®ç¯å²ã
ååšããããšãæããã«ãªã€ããããªãã¡100äž
æªæºã®æé€éçååéãæã€æ äœãçšããå Žåã¯
LDLã®é€å»éã¯å°ããå®çšã«èããªãããæé€
éçååéã100äžä¹è³æ°çŸäžãšLDLã®ååéã«
è¿ãæ äœã§ãããçšåºŠå®çšã«äŸãããåžçäœãåŸ
ããããäžæ¹æé€éçååéãšLDLã®åžçéã
ããã³LDL以å€ã®èçœè³ªã®åžçïŒããããéç¹
ç°åžçïŒãšã®é¢ä¿ã調ã¹ããšãæé€éçååéã
倧ãããªãã«ã€ãLDLã®åžçéãå¢å ãããã
ãã®å¢å ã¯æé€éçã1000äžãè¶ ãããšé æã¡ãš
ãªããäžæ¹LDL以å€ã®èçœãäŸãã°IGGãIGMç
ã®åžçãç®ç«ã€ããã«ãªãããšãããã€ãããã
ã«æé€éçååéãïŒå以äžã«ãªããšãªã¬ã³ãã®
åºå®åéãæžå°ããŠçµæçã«LDLã®åžçéãæž
ããéç¹ç°åžçãç¡èŠã§ããªããªããåŸã€ãŠæ¬çº
æã«çšããæ äœã®å¥œãŸããæé€éçååéã¯100
äžä»¥äžïŒå以äžã§ãããæã奜ãŸããã¯300äžä»¥
äž7000äžä»¥äžã§ããã 次ã«æ äœã®å€åæ§é ã«ã€ããŠã¯è¡šé¢å€åæ§ãã
ãå šå€åæ§ã奜ãŸããã空å容ç©ã20ïŒ ä»¥äžã§ã
ãããšã奜ãŸãããæ äœã®åœ¢ç¶ã¯ãç²ç¶ãç¹ç¶
ç¶ãèç¶ããããŒãã¢ã€ããŒç¶çä»»æã®åœ¢ç¶ãéž
ã¶ããšãã§ãããç²åç¶ã®æ äœãçšããå Žåãã
ã®ç²ååŸã¯ïŒÎŒä»¥äž5000Ό以äžã§ããã®ãæãŸã
ãã ããã«æ äœè¡šé¢ã«ã¯åºå®ååå¿ã«çšãåŸãå®èœ
åºãããã¯å®¹æã«æŽ»æ§åãåŸãå®èœåºãååšããŠ
ãããšå¥œéœåã§ããããããã®å®èœåºã®ä»£è¡šäŸãš
ããŠã¯ãã¢ããåºãã«ã«ããã·ã«åºãããããã·
ã«åºãããªãŒã«åºãé žç¡æ°Žç©åºããµã¯ã·ãã«ã€ã
ãåºãå¡©çŽ åºãã¢ã«ãããåºãã¢ããåºããšãã
ã·åºçããããããã æ¬çºæã«é©ããããªããŒããŒãã²ã«ã®ä»£è¡šäŸãš
ããŠã¯ãã¹ãã¬ã³âãžããã«ãã³ãŒã³å ±éåäœã
æ¶æ©ããªããã«ã¢ã«ã³ãŒã«ãæ¶æ©ããªã¢ã¯ãªã¬ãŒ
ããæ¶æ©ãããããã«ãšãŒãã«âç¡æ°Žãã¬ã€ã³é ž
å ±éåäœãæ¶æ©ãããã¹ãã¬ã³âç¡æ°Žãã¬ã€ã³é ž
å ±éåäœãæ¶æ©ããªã¢ããçã®åæé«ååãå€å
質ã»ã«ããŒã¹ã²ã«çã®ç¡¬è³ªå€åäœãããã³ããã
ã®è¡šé¢ã«å€ç³é¡ãåæé«ååçãã³ãŒãã€ã³ã°ã
ããã®çãããããããããããã«éå®ãããã
ãã§ã¯ãªãããããã®ããªããŒããŒãã²ã«ã¯åç¬
ã§çšããŠããããïŒçš®é¡ä»¥äžæ··åããŠçšããŠãã
ãã æ¬çºæã«çšããã«é©ãããªãèçœã«èŠªåæ§ãæ
ããããªã¢ããªã³ååç©ã®ä»£è¡šäŸãšããŠã¯ããã
ãªã³ãããã¹ãã©ã³ç¡«é žãã³ã³ããã€ãã³ç¡«é žã
ã³ã³ããã€ãã³ããªç¡«é žãããã©ã³é žãã±ã©ã¿ã³
ç¡«é žããããªãã³ç¡«é žããã·ã©ã³ç¡«é žãã«ããã³
ç¡«é žãã»ã«ããŒã¹ç¡«é žãããã³ç¡«é žããããµã³ç¡«
é žããã¯ãã³ç¡«é žãã€ããªã³ç¡«é žãã¢ã«ã®ã³é žç¡«
é žãã°ãªã³ãŒã²ã³ç¡«é žãããªã©ã¯ããŒã¹ç¡«é žãã«
ã©ã²ãã³ç¡«é žããã³ãã³ç¡«é žãããªã°ã«ã³ãŒã¹ç¡«
é žãã©ãããªã³ç¡«é žãã¬ã©ã¯ã¿ã³ç¡«é žãã¬ãã³ç¡«
é žãã¡ããµã«ããšãŒãçã®ç¡«é žåå€ç³ããªã³ã¿ã³
ã°ã¹ãã³é žãããªç¡«é žåã¢ãããŒã«ãããªããã«
ã¢ã«ã³ãŒã«ç¡«é žãããªãªã³é žçãããããããæ
ã奜ãŸããäŸãšããŠã¯ããããªã³ãããã¹ãã©ã³
ç¡«é žãã³ã³ããã€ãã³ããªç¡«é žããããããã ãªãèçœã«èŠªåæ§ãæããååç©ïŒãªã¬ã³ãïŒ
ãæ äœã«åºå®ããæ¹æ³ãšããŠã¯æ¢ç¥ã®çš®ã ã®æ¹æ³
ãçšããããšãã§ãããããªãã¡ç©ççåžçæ³ã
ã€ãªã³çµåæ³ãå ±æçµåæ³çã§ãããæ¬çºæã«ã
ãåžçäœãæ²»çã«çšããã«ã¯ãæ» èæãããã¯æ²»
çäžã«ãªã¬ã³ããè±é¢ããªãããšãéèŠã§ããã®
ã§çµåã®åŒ·åºãªå ±æçµåæ³ãæãŸãããã€ãªã³çµ
åæ³ãçšããã«ããŠããªã¬ã³ããå ±æçµåçã«æ¶
æ©ããŠããããšãæãŸããããŸãå¿ èŠã«ããã¹ã
ãŒãµãŒãæ äœãšãªã¬ã³ãã®éã«å°å ¥ããŠãããã ãªã¬ã³ãã®åºå®åéã«ã€ããŠã¯ããªã¬ã³ãã®æ§
ç¶ã掻æ§ã«ããç°ãªãããææã®ãªãèçœåžçé
ãåŸãã«ã¯ã«ã©ã äœç©ïŒmlããã0.02mg以äžã奜
ãŸããããŸãçµæžæ§ãèæ ®ãããš100mg以äžãæ
ãŸãããããã«å¥œãŸããã¯ã«ã©ã äœç©ïŒmlããã
0.5mg以äž20mg以äžã§ããã æ¬çºæã«ããåžçäœãæ²»çã«çšããã«ã¯çš®ã ã®
æ¹æ³ããããæã簡䟿ãªæ¹æ³ãšããŠã¯æ£è ã®è¡æ¶²
ãäœå€ã«å°åºããŠè¡æ¶²ããã°çã«è²¯ããããã«æ¬
çºæã®åžçäœïŒç²åïŒãæ··åããŠLDLãé€å»ã
ãåŸããã€ã«ã¿ãŒãéããŠåžçäœïŒç²åïŒãé€å»
ãè¡æ¶²ãæ£è ã«æ»ãæ¹æ³ãããããã®æ¹æ³ã¯è€é
ãªè£ 眮ãå¿ èŠãšããªãããïŒåã®åŠçéãå°ãªã
æ²»çã«æéãèŠããæäœãç ©éã«ãªããšããæ¬ ç¹
ãæããã次ã®æ¹æ³ã¯åžçäœãã«ã©ã ã«å å¡«ãã
äœå€åŸªç°åè·¯ã«çµã¿èŸŒã¿ãªã³ã©ã€ã³ã§åžçé€å»ã
è¡ãªããã®ã§ãããåŠçæ¹æ³ã«ã¯å šè¡ãçŽæ¥ãã
æµããæ¹æ³ãšãè¡æ¶²ããè¡æŒ¿ãåé¢ããåŸãè¡æŒ¿
ãã«ã©ã ã«éãæ¹æ³ããããæ¬çºæã«ããåžçäœ
ã¯ããããã®æ¹æ³ã«ãçšããããšãã§ããããå
è¿°ã®ããšããªã³ã©ã€ã³åŠçã«æãé©ããŠããã æ¬çºæã«ããåžçäœãçšããŠLDLãé€å»ãã
éãåŠçããããšããè¡æ¶²ããããã¯è¡æŒ¿ã«å€äŸ¡
éå±ã€ãªã³ãæ·»å ããããšã«ããé€å»å¹çãéžæ
æ§ãåäžãããããšãå¯èœã§ããããã®ç®çã«çš
ããå€äŸ¡éå±ã€ãªã³ãšããŠã¯ãã«ã«ã·ãŠã ããã°
ãã·ãŠã ãããªãŠã ãã¹ããã³ããŠã çã®ã¢ã«ã«
ãªåé¡éå±ã€ãªã³ãã¢ã«ãããŠã çã®å±å çŽ ã€
ãªã³ããã³ã¬ã³çã®å±å çŽ ã€ãªã³ãã³ãã«ãç
ã®å±å çŽ ã€ãªã³çããããããã 以äžå®æœäŸã«ããæ¬çºæãããã«è©³ãã説æã
ãã åèäŸ äž¡ç«¯ã«ååŸ15ÎŒïœã®ãã€ã«ã¿ãŒãè£ çããã¬ã©
ã¹è£œåçã«ã©ã ïŒå åŸïŒmmãã«ã©ã é·150mmïŒã«
ã¢ã¬ããŒã¹ã²ã«ïŒBiorad瀟補Biogel A5mãç²åŸ
50ã100ã¡ãã·ãŠïŒãããªããŒããŒãã²ã«ïŒæ±æŽæ¹
éå·¥æ¥(æ ª)補ããšããŒã«HW65ãç²åŸ50ã100ÎŒ
ïœãããã³ãããœ(æ ª)補ã»ã«ããã¢ã€ã³GCâ700ã
ç²åŸ45ã105ÎŒïœïŒãããããåäžã«å å¡«ããã
ãªã¹ã¿ãã€ãã¯ãã³ãã«ããæ°Žãæµããæµéãšå§
åæ倱ã®é¢ä¿ãæ±ãããçµæãå³ïŒã«ç€ºãããã
ã«ãããšããªããŒããŒãã²ã«ãå§åã®å¢å ã«ã»ãŒ
æ¯äŸããŠæµéãå¢å ããã®ã«å¯Ÿããã¢ã¬ããŒã¹ã²
ã«ã¯å§å¯åãã²ããããå§åãå¢å ãããŠãæµé
ãå¢å ããªãããšã瀺ããŠããã å®æœäŸ ïŒ æ¶æ©ã¢ã¯ãªã¬ãŒãã²ã«ïŒå šå€åæ§ã®ããŒãã²
ã«ïŒã§ããããšããŒã«HW55ïŒçç¶èçœè³ªã®æé€
éçååéïŒä»¥äžèçœè³ªã®æé€éçãšç¥ç§°ããïŒ
700000ãç²åŸã50ã100ÎŒïœïŒãHW60ïŒèçœè³ªã®
æé€éç1000000ãç²åŸ50ã100ÎŒïœïŒãHW65
ïŒèçœè³ªã®æé€éç5000000ãç²åŸ50ã100ÎŒïœïŒã
HW75ïŒèçœè³ªã®æé€éç50000000ãç²åŸ50ã
100ÎŒïœïŒå10mlã«é£œåNaOH氎溶液ïŒmlããšã
ã¯ãã«ãããªã³15mlãå ãæ¹æããªãã50âã§ïŒ
æéåå¿ããšããã·åã²ã«ãåŸãããã®ã²ã«ã«æ¿
ã¢ã³ã¢ãã¢æ°Ž20mlãå ã50âã§ïŒæéæ¹æãã¢ã
ãåºãå°å ¥ããã 次ã«ãããªã³200mgã10mlã®æ°Žã«æº¶è§£ãPH4.5ã«
調æŽããåŸãããã«ïŒmlã®äžèšã¢ããåºå«æã²ã«
ãå ãããããã«ïŒâãšãã«âïŒâïŒãžã¡ãã«ã¢
ãããããã«ïŒâã«ã«ããžã€ãã200mgãPHã4.5
ã«ä¿ã¡ãªããæ·»å ãïŒâã§24æéæ¯ãšããããå
å¿çµäºåŸãïŒã¢ã«é£å¡©æº¶æ¶²ã0.5ã¢ã«é£å¡©æº¶æ¶²ã
æ°Žã§æŽæµããããªã³åºå®åã²ã«ãåŸããåºå®åã
ãããããªã³ã®éã¯ãããã2.2mgïŒmlã1.8mgïŒ
mlã1.4mgïŒmlã0.8mgïŒmlã§ãã€ãã å®æœäŸ ïŒ ç¡¬è³ªã»ã«ããŒã¹å€åäœïŒå šå€åæ§ã®ããŒãã²
ã«ïŒãã»ã«ããã¢ã€ã³GC700ïŒãããœ(æ ª)補ãèçœ
質ã®æé€éç400000ãç²åŸ45ã105ÎŒïœïŒãã»ã«ã
ãã¢ã€ã³ïŒ¡âïŒïŒãããœ(æ ª)補ïŒè©ŠäœåïŒãèçœè³ª
ã®æé€éç700000ãç²åŸ45ã105ÎŒïœïŒãã»ã«ãã
ã¢ã€ã³ïŒ¡âïŒïŒãããœ(æ ª)補ïŒè©ŠäœåïŒãèçœè³ªã®
æé€éççŽ50000000ãç²åŸ45ã105ÎŒïœïŒããã
ããåžåŒéããå10gããšããããã«20ïŒ
NaOHã4gãããã¿ã³12gãå ããããã«ãããª
ã³ç³»çé¢æŽ»æ§å€TWEEN20ãïŒæ»Žå ãæ¹æããŠã²
ã«ãåæ£ãããã40âã§ïŒæéæ¹æåŸãããã«ãš
ãã¯ãã«ãããªã³5gãå ã40âã§ïŒæéæ¹æã
ããé眮åŸãäžæŸã¿ãæšãŠãã²ã«ãæ°ŽæŽéããŠ
ãšããã·åã²ã«ãåŸããããã«15mlã®æ¿ã¢ã³ã¢ã
ã¢æ°Žãå ã40âã§1.5æéæ¹æããå 容ç©ãåžåŒ
éãæ°ŽæŽããŠã¢ããåºã®å°å ¥ãããã»ã«ããŒã¹
ã²ã«ãåŸãã 次ã«ãããªã³200mgã10mlã®æ°Žã«æº¶è§£ãããã
ã«äžèšã¢ããåºå«æã²ã«ïŒmlãå ããŠPH4.5ã«èª¿
æŽãããããã«ïŒâãšãã«âïŒâïŒãžã¡ãã«ã¢ã
ããããã«ïŒâã«ã«ããžã€ãã200mgãPH4.5ã«ä¿
ã¡ãªããæ·»å ããïŒâã§24æéæ¯ãšããããåå¿
çµäºåŸãïŒã¢ã«é£å¡©æº¶æ¶²ã0.5ã¢ã«é£å¡©æº¶æ¶²ãæ°Ž
ã§æŽæµããããªã³åºå®åã²ã«ãåŸããåºå®åãã
ããããªã³éã¯ãããã2.5mgïŒmlã2.2mgïŒmlã
1.8mgïŒmlã§ãã€ãã å®æœäŸ ïŒ ãããªã³ãã³ã³ããã€ãã³ããªç¡«é žã«ãããä»
ã¯å®æœäŸïŒãšåãæ¹æ³ã§ã³ã³ããã€ãã³ããªç¡«é ž
åºå®åããšããŒã«ã²ã«HW65ãåŸããåºå®åéã¯
1.2mgïŒmlã§ãã€ãã å®æœäŸ ïŒ ã»ã«ããã¢ã€ã³ïŒ¡âïŒ ïŒmlã«0.5ã¢ã«NaIO4
ãå ããŠ10mlãšãïŒæé宀枩ã§æ¹æåŸãéæ°ŽæŽ
ããŠã¢ã«ãããåºãå°å ¥ããã次ã«ãã®ã²ã«ãPH
ïŒã®ãªã³é žç·©è¡æ¶²10mläžã«æžæ¿ãããžãšãã«ã¢ã
ã³50mgãå ããŠå®€æž©ã§20æéæ¹æãå¥ãããã
ããïŒïŒ NaBH4溶液10mläžã«æžæ¿ã15åééå
åŸãéãæŽæµããŠã¢ããåºãå°å ¥ããã 次ã«ããã¹ãã©ã³ç¡«é ž300mgã0.25ã¢ã«NaIO4
溶液10mlã«æº¶è§£ã宀枩ã§ïŒæéæ¹æåŸããšãã¬ã³
ã°ãªã³ãŒã«200mgãå ããŠïŒæéæ¹æããããã®
溶液ãPHïŒã«èª¿æŽããåŸãäžèšã¢ããåºå«æã²ã«
ãæžæ¿ã24æéæ¹æãããåå¿çµäºåŸãã²ã«ã
éãæ°ŽæŽãããããïŒïŒ NaBH4溶液10mlã«æžæ¿
ã15åééå ããéæ°ŽæŽããŠããã¹ãã©ã³ç¡«é ž
åºå®åã»ã«ããŒã¹ã²ã«ãåŸããåºå®åéã¯0.5
mgïŒmlã§ãã€ãã å®æœäŸ ïŒ å®æœäŸïŒãïŒã§åæããåžçäœåïŒmlãè©Šéšç®¡
ã«ãšããããã«äººè¡æŒ¿ïŒmlïŒCaCl20.02Må«æïŒ
ãå ããŠæ¹æãã20âã§15åéé眮åŸãäžæŸã¿ã®
ã³ã¬ã¹ãããŒã«æ¿åºŠããã³LDLïŒÎ²âãªãè
çœïŒéã枬å®ãããçµæãè¡šïŒã«ç€ºãã
ãè¡šã
å³ïŒã¯ãåèäŸã«ãããŠåçš®ã²ã«ãçšããŠæµé
ãšå§åæ倱ã®é¢ä¿ã調ã¹ãã°ã©ãã§ããã
ãšå§åæ倱ã®é¢ä¿ã調ã¹ãã°ã©ãã§ããã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ çç¶èçœè³ªã®æé€éçååéã100äžä»¥äžïŒ
å以äžã®ããŒã©ã¹ããªããŒããŒãã²ã«ã«ããªãè
çœã«èŠªåæ§ãæããããªã¢ããªã³ååç©ãåºå®ã
ãŠãªããªãèçœåžçäœã ïŒ ããŒã©ã¹ããªããŒããŒãã²ã«ãåæé«ååã
ããªãç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®åžçäœã ïŒ ããŒã©ã¹ããªããŒããŒãã²ã«ãå€å質ã»ã«ã
ãŒã¹ã²ã«ã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®åžç
äœã ïŒ ããªã¢ããªã³ååç©ãç¡«é žåå€ç³ã§ããç¹èš±
è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®åžçäœã ïŒ ç¡«é žåå€ç³ããããªã³ãããã¹ãã©ã³ç¡«é žã
ã³ã³ããã€ãã³ããªç¡«é žããéžã°ããå°ããšãïŒ
çš®ã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®åžçäœã ïŒ ããªã¢ããªã³ååç©ã®åºå®åéãã«ã©ã äœç©
ïŒmlããã0.02mg以äž100mg以äžã§ããç¹èš±è«æ±
ã®ç¯å²ç¬¬ïŒé èšèŒã®åžçäœã
Priority Applications (16)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57212379A JPS59102436A (ja) | 1982-12-02 | 1982-12-02 | åžçäœ |
| AU21832/83A AU571855B2 (en) | 1982-12-02 | 1983-11-30 | Adsorbent for removing harmful substances from blood |
| ZA838908A ZA838908B (en) | 1982-12-02 | 1983-11-30 | Absorbent and process for preparing the same |
| CA000442312A CA1221307A (en) | 1982-12-02 | 1983-11-30 | Adsorbent and process for preparing the same |
| DE87100215T DE3382723T2 (de) | 1982-12-02 | 1983-12-01 | Adsorbens und Verfahren zu dessen Herstellung. |
| AT87100215T ATE97832T1 (de) | 1982-12-02 | 1983-12-01 | Adsorbens und verfahren zu dessen herstellung. |
| US06/557,061 US4576928A (en) | 1982-12-02 | 1983-12-01 | Adsorbent and process for preparing the same |
| DE3382834T DE3382834T3 (de) | 1982-12-02 | 1983-12-01 | Sorbentmittel und dessen Herstellungsverfahren |
| EP83112042A EP0110409B2 (en) | 1982-12-02 | 1983-12-01 | Adsorbent and process for preparing the same |
| DE8383112042T DE3379644D1 (en) | 1982-12-02 | 1983-12-01 | Adsorbent and process for preparing the same |
| EP91115793A EP0464872B2 (en) | 1982-12-02 | 1983-12-01 | Adsorbent and process for preparing the same |
| AT83112042T ATE42222T1 (de) | 1982-12-02 | 1983-12-01 | Adsorbent und verfahren zu dessen herstellung. |
| EP87100215A EP0225867B1 (en) | 1982-12-02 | 1983-12-01 | Adsorbent and process for preparing the same |
| AT91115793T ATE195891T1 (de) | 1982-12-02 | 1983-12-01 | Sorbentmittel und dessen herstellungsverfahren |
| US06/737,880 US4637994A (en) | 1982-12-02 | 1985-05-28 | Adsorbent and process for preparing the same |
| AU12621/88A AU598643B2 (en) | 1982-12-02 | 1988-03-01 | Adsorbent and process for preparing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57212379A JPS59102436A (ja) | 1982-12-02 | 1982-12-02 | åžçäœ |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63249652A Division JPH01145071A (ja) | 1988-10-03 | 1988-10-03 | ãªãèçœãé€å»ããè¡æŒ¿ã®è£œé æ¹æ³ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS59102436A JPS59102436A (ja) | 1984-06-13 |
| JPS6256782B2 true JPS6256782B2 (ja) | 1987-11-27 |
Family
ID=16621591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57212379A Granted JPS59102436A (ja) | 1982-12-02 | 1982-12-02 | åžçäœ |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JPS59102436A (ja) |
| ZA (1) | ZA838908B (ja) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61268355A (ja) * | 1985-05-23 | 1986-11-27 | Kanegafuchi Chem Ind Co Ltd | äœå€åŸªç°æ²»ççšãªãèçœåžçäœããã³ãã®è£œæ³ |
| JPH0659309B2 (ja) * | 1985-07-23 | 1994-08-10 | æåæå·¥æ¥æ ªåŒäŒç€Ÿ | äœæ¯éãªãèçœè³ªåžçè£ çœ® |
| JP2005315666A (ja) * | 2004-04-28 | 2005-11-10 | Toshihiko Hanai | ç³çµåå å¡«å€ããã³ãã®è£œé æ¹æ³ |
| CN100455349C (zh) * | 2006-03-28 | 2009-01-28 | å京èµéŠå»ççšåæéå ¬åž | çšäºè¡æ¶²äœå€åŸªç¯å»é€äœå¯åºŠèèçœçåžéååå ¶å¶æ³ |
| US20140054227A1 (en) * | 2011-03-04 | 2014-02-27 | Dic Corporation | Sugar-immobilized polymer substrate for removing virus and method for removing virus |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS525393A (en) * | 1975-06-25 | 1977-01-17 | Ajinomoto Kk | Production of carboxy alkylation substance |
| JPS5493689A (en) * | 1977-12-02 | 1979-07-24 | Baylor College Medicine | Resin of selectively removing antibacterial from bacteria infected sap sample and its use |
| JPS57190003A (en) * | 1981-05-18 | 1982-11-22 | Asahi Chem Ind Co Ltd | Wholly porous activated gel |
| JPS5812656A (ja) * | 1981-07-17 | 1983-01-24 | æåææ ªåŒäŒç€Ÿ | äœå€åŸªç°æ²»ççšåžçæ |
-
1982
- 1982-12-02 JP JP57212379A patent/JPS59102436A/ja active Granted
-
1983
- 1983-11-30 ZA ZA838908A patent/ZA838908B/xx unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS525393A (en) * | 1975-06-25 | 1977-01-17 | Ajinomoto Kk | Production of carboxy alkylation substance |
| JPS5493689A (en) * | 1977-12-02 | 1979-07-24 | Baylor College Medicine | Resin of selectively removing antibacterial from bacteria infected sap sample and its use |
| JPS57190003A (en) * | 1981-05-18 | 1982-11-22 | Asahi Chem Ind Co Ltd | Wholly porous activated gel |
| JPS5812656A (ja) * | 1981-07-17 | 1983-01-24 | æåææ ªåŒäŒç€Ÿ | äœå€åŸªç°æ²»ççšåžçæ |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS59102436A (ja) | 1984-06-13 |
| ZA838908B (en) | 1984-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0464872B1 (en) | Adsorbent and process for preparing the same | |
| JPH0434451B2 (ja) | ||
| EP1621220B1 (en) | Low density lipoprotein/fibrinogen adsorbent and adsorption apparatus capable of whole blood treatment | |
| JPS6256782B2 (ja) | ||
| JPS59193135A (ja) | åžçäœ | |
| JPS6319214B2 (ja) | ||
| JPS62192172A (ja) | åžçäœ | |
| JPH0611333B2 (ja) | å ç«è€åäœã®åžçäœããã³ãããçšããå ç«è€åäœã®é€å»è£ 眮 | |
| JPH0362433B2 (ja) | ||
| JPH0339736B2 (ja) | ||
| JPS59186559A (ja) | èªå·±æäœããã³ïŒãŸãã¯å ç«è€åäœåžçæ | |
| JP3157026B2 (ja) | è¡æ¶²æµåçšåžçæ | |
| JPH0622632B2 (ja) | åžçäœããã³é€å»è£ 眮 | |
| JPH11332981A (ja) | è¡äžã®äœå¯åºŠãªãèçœè³ªé€å»æ¹æ³ | |
| JP4141224B2 (ja) | äœå¯åºŠãªãèçœããã³ãã£ããªããŒã²ã³ã®åžçæãåã³ãã®åžçåš | |
| JP2726662B2 (ja) | åžçäœããã³ãããçšããé€å»è£ 眮 | |
| JPH0771632B2 (ja) | åžçäœããã³ãããçšããé€å»è£ 眮 | |
| JPH0513697B2 (ja) | ||
| JP2983955B2 (ja) | è 糞çäœåºåºèä»çæ§èçœè³ªã®é€å»è£ 眮 | |
| JPH04227268A (ja) | åžçäœã®è£œé æ³ | |
| JPS62244442A (ja) | äœæ¯éãªãèçœè³ªåžçæããã³ãã®è£œé æ¹æ³ | |
| JPH035822B2 (ja) | ||
| JPS6077769A (ja) | åžçäœã®è£œé æ³ | |
| JPH0622624B2 (ja) | äœæ¯éãªãèçœè³ªåžçæã®åçæ¹æ³ | |
| JPH0611335B2 (ja) | åžçäœããã³é€å»è£ 眮 |